Cetuximab Monoclonal Antibody from China
Cetuximab (Erbitux) targets EGFR for colorectal and head/neck cancer therapy, a chimeric monoclonal antibody. Bulk unmixed form imports under HTS 3002.13.0010 as a biotech immunological product per chapter note definitions. Excludes retail or dosed packings.
Duty Rate — China → United States
100%
Rate breakdown
9903.04.60100%Pharmaceuticals: patented pharma articles — 100% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Require DEA scheduling check if any narcotic analogs present (rare for monoclonals)
• Use ISF filings 24hrs prior with detailed biotech manufacturing specs
• Ensure no 'mixed' status per note 3(b) to stay in unmixed category